NCT07105709View on ClinicalTrials.gov

Open-label Extension Study in Participants With Early Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

August 14, 2025

Primary Completion Date

September 1, 2028

Study Completion Date

November 24, 2028

Conditions
Alzheimer's Disease
Interventions
DRUG

GSK4527226

GSK4527226 will be administered.

Trial Locations (5)

33176

RECRUITING

GSK Investigational Site, Miami

08755

RECRUITING

GSK Investigational Site, Toms River

K9H 2P4

RECRUITING

GSK Investigational Site, Peterborough

J4V 2J2

RECRUITING

GSK Investigational Site, Greenfield Park

J1J 2G2

RECRUITING

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Alector Inc.
All Listed Sponsors
collaborator

Alector Inc.

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT07105709 - Open-label Extension Study in Participants With Early Alzheimer's Disease | Biotech Hunter | Biotech Hunter